Changes in Trypanosoma cruzi-specific immune responses following treatment: surrogate markers of treatment efficacy

BACKGROUND: As many as 20 million people are living with Trypanosoma cruzi infection in Latin American, yet few receive any treatment. The major limitation in developing and evaluating potential new drugs for their efficacy is the lack of reliable tests to assess parasite burden and elimination. MET...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Laucella, Susana A., Mazliah, Damián Pérez, Bertocchi, Graciela, Alvarez, María G., Cooley, Gretchen, Viotti, Rodolfo, Albareda, María C., Lococo, Bruno, Postan, Miriam, Armenti, Alejandro, Tarleton, Rick L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2805187/
https://ncbi.nlm.nih.gov/pubmed/19877967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/648072
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky